Compare Davita Inc (DVA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Procter & Gamble Co — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Procter & Gamble Co trades at $151.2 (market cap $349.77B). The key difference: Procter & Gamble Co is far larger — about 31× Davita Inc's market cap, and Procter & Gamble Co pays a 2.89% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Procter & Gamble Co for 131 Days on average.
| DVA | PG | |
|---|---|---|
Market Cap | $11.29B | $349.77B |
Volume | 582,204 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $167.18 |
52-Week Low | $103.87 | $138.10 |
Typical Hold Time | 114 Days | 131 Days |
Enterprise Value | $24.01B | $375.61B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
Procter & Gamble (PG) trades at $151.23, up 2.31% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and consistent earnings beats. Recent partnership with the WNBA and supply chain enhancements support growth. Technical indicators show bullish moving averages while RSI remains neutral.
PG offers stable dividend income with 69-year growth history and trades near consensus target of $160.13. Premium valuation metrics present near-term risk if growth moderates. Strong cash flow generation and institutional support provide downside protection amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
